Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.51 |
| ▸ | GIPR | P48546 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647002 | 1.00 | GCGR (0.51) | GCGRGIPRTRPV1CHRM2CHRM1 | |
| SCHEMBL2647008 | 1.00 | GCGR (0.51) | GCGRGIPRTRPV1CHRM2CHRM1 | |
| SCHEMBL2665131 | 0.91 | GCGR (0.46) | GCGRGIPRTRPV1CHRM2CHRM1 | |
| SCHEMBL6917347 | 0.89 | GCGR (0.58) | GCGRGIPRTRPV1EPHX2PPARG | |
| SCHEMBL6917344 | 0.89 | GCGR (0.58) | GCGRGIPRTRPV1EPHX2PPARG | |
| SCHEMBL2665219 | 0.89 | GCGR (0.58) | GCGRGIPRTRPV1EPHX2PPARG | |
| SCHEMBL9071437 | 0.86 | GCGR (0.58) | GCGRGIPRTRPV1EPHX2PPARG | |
| SCHEMBL9071390 | 0.85 | GCGR (0.42) | GCGRGIPREPHX2 | |
| SCHEMBL2648042 | 0.85 | GCGR (0.53) | GCGRGIPRTRPV1CHRM2CHRM1 | |
| SCHEMBL2648150 | 0.85 | GCGR (0.53) | GCGRGIPRTRPV1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885GIPR 3/4885TRPV1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.